Product Description
Mechanisms of Action: TH2 Cytokine Receptor Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: India
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Idiopathic Pulmonary Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| COSMIC-IPF | P2 |
Recruiting |
Idiopathic Pulmonary Fibrosis |
2025-08-01 |